Reference:
[1]. Nobuko Hijiya1 and Meinolf Suttorp2. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374-2384.
[2]. J.-M. Cayuela1, F. Huguet2 Le diagnostic de la leucémie myéloïde chronique (LMC) en 2012. Oncologie (2012) 14: 561–568.
[3]. Sebastian Kreil, 1,2 Markus Pfirrmann, 3,4 Claudia Haferlach, 5 et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia, Blood  (2007) 110 (4): 1283–1290.
[4]. Elias Jabbour, Hagop Kantarjian, Susan O’Brien, et al. Cortes Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood  (2011) 117 (6): 1822–1827.
[5]. Baccarani M, Saglio G, Goldman J, et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809–20.
[6]. Meyran, Deborah. ”Leucémie myéloïde chronique chez l’enfant, une pathologie rare et unique.” Médecine thérapeutique/Pédiatrie 22.2 (2019): 108-116.
[7].Jean-MichelCayuela12Jean ClaudeChomel12ValérieCoiteux1, et al. Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1  kinase domain mutation analysis in chronic myeloid leukemia. Bulletin du Cancer, Volume 107, Issue 1, January 2020, Pages 113-128.